Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $8.0 million.

  • Atara Biotherapeutics' Short-term Investments fell 6156.44% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 6156.44%. This contributed to the annual value of $17.5 million for FY2024, which is 3252.2% down from last year.
  • As of Q3 2025, Atara Biotherapeutics' Short-term Investments stood at $8.0 million, which was down 6156.44% from $5.4 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Short-term Investments high stood at $260.6 million for Q2 2022, and its period low was $146000.0 during Q1 2025.
  • Its 4-year average for Short-term Investments is $80.4 million, with a median of $25.9 million in 2023.
  • Over the last 5 years, Atara Biotherapeutics' Short-term Investments had its largest YoY gain of 3624.94% in 2025, and its largest YoY loss of 9869.08% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Short-term Investments stood at $149.9 million in 2022, then plummeted by 82.73% to $25.9 million in 2023, then tumbled by 32.52% to $17.5 million in 2024, then crashed by 54.37% to $8.0 million in 2025.
  • Its Short-term Investments was $8.0 million in Q3 2025, compared to $5.4 million in Q2 2025 and $146000.0 in Q1 2025.